Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

Inherited Cardiac cONditions In Kids

Sponsor: Imperial College London

NCT ID: NCT05158738

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Patients with inherited cardiac condition, onset <16 years old and Parents (other)
How long the study runs
Study runs about 51 months (dates as stated)
About the drug or intervention
Patients with inherited cardiac condition, onset <16 years old and Parents — other: Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
Not specified
Who
All
Number of participants
300
Started
2022-09-01
Last checked
2025-03

Plain English Summary

What is this study?

  • • Testing a new treatment for inherited cardiac conditions
  • • Clinical study - 300 participants
  • • All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment

Who can take part?

  • • Adults
  • • Diagnosed with inherited cardiac conditions

Where?

  • • London - Royal Brompton Hospital
  • • London - Great Ormond Street Hospital for Children
  • • Uxbridge - Harefield Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment. The investigators have built an online registry and database - The Heart Hive - to connect research-willing participants (with heart muscle disease) with active researchers and projects. Participants enrol and upload their own data through the website.This study uses The Heart Hive platform to study cardiomyopathies - heart muscle disease. These are progressive diseases, and there is a need to better understand what factors affect the chances of developing cardiomyopathy, and how the condition progresses. The study will collect information about participants diagnosis, DNA for genetic analysis, and then follow participants' clinical progress. The study will identify genetic variants that cause cardiomyopathy, and determine which specific genetic or environmental factors predict disease severity, progression and response to treatment, with an overall objective of identifying new and personalised treatments for patients with this disease.

More detail

This is a multi-centre, observational study of children with rare inherited cardiac conditions. The focus of the study will be on children with clinically diagnosed cardiomyopathy and their unaffected parents, with collection of baseline demographic data, imaging data, and genotyping data. Children and their parents will been rolled over a 5-year period. Sub-sets of patients with confirmed diagnoses of other heritable cardiovascular diseases with onset \<16 years will also be recruited.These will include children who following evaluation by their clinical multidisciplinary team (which will include a geneticist or genetic counsellor) are likely to have a rare monogenic condition. Other affected family members of eligible patients may be also invited to participate in the study. Information for this study will be collected primarily from investigations performed as part of the participants' routine clinical care including whole genome sequencing commissioned by NHS England. The study will seek consent to access and export this data. Procedures performed as part of this study may include venepuncture and/or saliva collection and carry minimal risk to the patient. Parents of participants that are recruited into the study will donate a blood sample (or saliva sample if unable to provide blood) and consent will be requested for collection of health information and results of relevant investigations carried out as part of their routine clinical care (e.g. an echocardiogram). Other family members that are recruited into the study will donate a blood sample (or saliva sample if unable to provide blood) and consent will be requested for collection of health information. Family members of deceased patients with cardiomyopathy or other inherited cardiac conditions may be asked if they wish to donate stored samples that may have been taken prior to death or as part of a post-mortem examination to establish cause of death. Any discussion with regard to the use of stored samples for this project will be initiated by the clinical care team for the deceased patient and their family to minimise any potential distress to the family. Sub-sets of patients may be asked to donate tissue samples taken as part of their clinical care.

Inherited Cardiac ConditionsCardiovascular Diseases

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: Not specified
  • Who can join: All genders

Biomarkers mentioned

Genotype negative

What the study is looking for

  • ✓Males or females with a confirmed diagnosis of childhood onset (\<16 years) PCM
  • ✓Males or females with childhood onset (\<16 years) of a rare inherited heart condition likely to be a monogenic...
  • ✓Capacity for parents to provide agreement to take part
  • ✓Genotype negative following local standard diagnostic ICC gene panel
  • ✓Family members of patients with ICC, both affected and unaffected

Who cannot take part

  • ✗Parents who lack capacity to provide consent on behalf of their children/themselves
  • ✗Onset over 16 years
  • ✗Significant teratogen exposure (including maternal diabetes) likely to contribute to heart dysfunction (following...
  • ✗Significant coronary heart disease likely to contribute to heart dysfunction (following discussion with Cardiologist)
  • ✗Other secondary causes of heart dysfunction likely to explain the phenotype of the patient
See the full criteria
Inclusion Criteria: * Males or females with a confirmed diagnosis of childhood onset (\<16 years) PCM * Males or females with childhood onset (\<16 years) of a rare inherited cardiac condition likely to be a monogenic condition * Capacity for parents to provide informed consent * Genotype negative following local standard diagnostic ICC gene panel * Family members of patients with ICC, both affected and unaffected Exclusion Criteria: * Parents who lack capacity to provide consent on behalf of their children/themselves * Onset over 16 years * Significant teratogen exposure (including maternal diabetes) likely to contribute to cardiac dysfunction (following discussion with Cardiologist) * Significant coronary heart disease likely to contribute to cardiac dysfunction (following discussion with Cardiologist) * Other secondary causes of cardiac dysfunction likely to explain the phenotype of the patient * Patients with a confirmed genetic diagnosis (patients with variants of uncertain significance are not excluded).

Where Is This Study? (3 UK sites)

Royal Brompton Hospital

London SW3 6NP, United Kingdom

Recruiting
Site contact (verified)
Piers Daubeney, ProfessorPrincipal Investigator

Great Ormond Street Hospital for Children

London, United Kingdom

Recruiting
Site contact (verified)
Angharad Roberts, DrPrincipal Investigator

Harefield Hospital

Uxbridge UB9 6JH, United Kingdom

Recruiting
Site contact (verified)
Andres Rico-Armada, DrPrincipal Investigator

How to Get in Touch

Katherine Josephs

Sponsor contact

CONTACT

0207 594 9459 k.josephs@imperial.ac.uk

Chief Investigator

Sponsor contact

CONTACT

0330 128 2294
Data sourced from ClinicalTrials.gov · Last verified: 2025-03